Skip to main content

Table 2 Baseline Characteristics

From: Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial

  LVPEG-1 LVPEG-2 LVPEG-3 Control LVPEG-3 LVPEG-4 LVPEG-5 Control
Study Part 1 1 1 1 2 2 2 2
Patients, n 30 30 30 30 30 30 30 30
Age, years (mean ± SD) 53.2 ± 8.2 53.4 ± 8.0 55.4 ± 8.2 51.2 ± 8.4 60.4 ± 5.7 60.0 ± 6.3 61.9 ± 6.7 58.8 ± 6.1
Gender, n (%)
 Male 17 (56.7) 17 (56.7) 18 (60.0) 18 (60.0) 14 (46.7) 13 (43.3) 13 (43.3) 14 (46.7)
 Female 13 (43.3) 13 (43.3) 12 (40.0) 12 (40.0) 16 (53.3) 17 (56.7) 17 (56.7) 16 (53.3)
Race, n (%)
 White or Caucasian 30 (100.0) 29 (96.7) 30 (100.0) 30 (100.0) 30 (100.0) 30 (100.0)a 30 (100.0) 30 (100.0)
 Other 0 1 (3.3) 0 0 0 0 0 0
BMI (kg/m2, mean ± SD) 25.4 (2.8) 25.5 (2.2) 25.2 (2.8) 25.0 (3.3) 25.4 (2.7) 25.9 (3.4) 25.8 (2.9) 25.4 (3.4)
  1. aOne subject, receiving LVPEG-4 in Part 2, was described as both Hispanic and White/Caucasian. SD, standard deviation; BMI, body mass index